Biohaven Pharmaceutical Current Valuation vs. Debt To Equity

BHVN Stock  USD 46.06  2.38  5.45%   
Taking into consideration Biohaven Pharmaceutical's profitability measurements, Biohaven Pharmaceutical Holding may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Biohaven Pharmaceutical's ability to earn profits and add value for shareholders. As of the 4th of December 2024, Price To Sales Ratio is likely to drop to 0.46. In addition to that, Days Sales Outstanding is likely to drop to 6.26. At this time, Biohaven Pharmaceutical's Total Other Income Expense Net is very stable compared to the past year. As of the 4th of December 2024, Change To Netincome is likely to grow to about 362 M, though Accumulated Other Comprehensive Income is likely to grow to (61.8 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.640.72
Fairly Down
Slightly volatile
For Biohaven Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biohaven Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biohaven Pharmaceutical Holding utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biohaven Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biohaven Pharmaceutical Holding over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.37)
Return On Assets
(1.19)
Return On Equity
(2.65)
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Biohaven Pharmaceutical Debt To Equity vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Biohaven Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Biohaven Pharmaceutical value to that of its competitors to determine the firm's financial worth.
Biohaven Pharmaceutical Holding is rated fifth in current valuation category among its peers. It is rated below average in debt to equity category among its peers . The ratio of Current Valuation to Debt To Equity for Biohaven Pharmaceutical Holding is about  19,148,538,009 . At this time, Biohaven Pharmaceutical's Debt To Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biohaven Pharmaceutical's earnings, one of the primary drivers of an investment's value.

Biohaven Current Valuation vs. Competition

Biohaven Pharmaceutical Holding is rated fifth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 41.98 Billion. Biohaven Pharmaceutical holds roughly 4.17 Billion in current valuation claiming about 10% of equities under Health Care industry.

Biohaven Debt To Equity vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Biohaven Pharmaceutical

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
4.17 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Biohaven Pharmaceutical

D/E

 = 

Total Debt

Total Equity

 = 
0.22 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Biohaven Debt To Equity Comparison

Biohaven Pharmaceutical is currently under evaluation in debt to equity category among its peers.

Biohaven Pharmaceutical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Biohaven Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Biohaven Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Biohaven Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Biohaven Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-65 K-61.8 K
Operating Income-436.1 M-457.9 M
Income Before Tax-409.6 M-430 M
Total Other Income Expense Net26.5 M27.8 M
Net Loss-408.2 M-428.6 M
Income Tax Expense-1.4 M-1.3 M
Net Loss-408.2 M-428.6 M
Net Loss-513.3 M-538.9 M
Non Operating Income Net Other-58.9 M-61.8 M
Change To Netincome344.8 M362 M
Net Loss(5.73)(6.02)
Income Quality 0.81  0.77 
Net Income Per E B T 1.00  1.10 

Biohaven Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Biohaven Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Biohaven Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Biohaven Pharmaceutical's important profitability drivers and their relationship over time.

Use Biohaven Pharmaceutical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Biohaven Pharmaceutical Pair Trading

Biohaven Pharmaceutical Holding Pair Trading Analysis

The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Biohaven Pharmaceutical position

In addition to having Biohaven Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run World Allocation Funds Thematic Idea Now

World Allocation Funds
World Allocation Funds Theme
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:
Check out Trending Equities.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
To fully project Biohaven Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Biohaven Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Biohaven Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.
Potential Biohaven Pharmaceutical investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Biohaven Pharmaceutical investors may work on each financial statement separately, they are all related. The changes in Biohaven Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biohaven Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.